medigraphic.com
ISSN 1995-9494 (Digital)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"

2016, Número 3

<< Anterior Siguiente >>

Acta Med Cent 2016; 10 (3)


Inhibidores del proteosoma: estrategia terapéutica en el síndrome linfoproliferativo crónico

López SA, García SD

Idioma: Español
Referencias bibliográficas: 31
Paginas: 78-87
Archivo PDF: 263.36 Kb.


RESUMEN

Hace 14 años se publicaron los primeros resultados de los ensayos clínicos fase I con el bortezomib, el primer inhibidor de los proteosomas; su introducción en la práctica clínica significó un mejoramiento en las tasas de remisión completa, de supervivencia global y libre de progresión en los pacientes con mieloma múltiple. Sus beneficios no se limitan al grupo de pacientes en recaída o refractarios con este diagnóstico, sino también a pacientes elegibles o no para trasplante de células hematopoyéticas como tratamiento de inducción, de consolidación y de mantenimiento. Recientemente un grupo de inhibidores de proteosomas de segunda generación, que brindan la posibilidad de administración oral y aplicación en casos en los que se comprueba resistencia a otros inhibidores del proteosoma, han sido introducidos en la clínica. En la actualidad los inhibidores de proteosomas constituyen una diana terapéutica prometedora en el manejo de algunas variedades de linfomas no Hodgkin.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012 Aug 2;120(5): 947–59. doi: 10.1182/blood-2012-04-403733. PMCID: PMC4123429

  2. He J, Yang L, Han X, Zheng G, Zheng W. The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma. PLoS ONE. 2014;9(6):e99174. doi:10.1371/journal.pone.0099174

  3. Manni S, Brancalion A, Mandato E, Tubi LQ, Colpo A. Protein Kinase CK2 Inhibition Down Modulates the NF-kB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE. 2013;8(9): e75280. doi:10.1371/journal.pone.0075280

  4. Kouroukis TC, Baldassamorre FC, Haynes AE, Imrie K, Reece DE, Cheung MC. Bortezomib in MM: systematic review and clinical considerations. Curr Oncol. 2014 Aug;21(4):573-603.

  5. Barosi G, Merlini G, Billio A. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Ann Hematol. 2012;91:875–88. doi: 10.1007/s00277-012-1445-y.

  6. Hjorth M, Hjertner O, Knudsen LM. On behalf of the Nordic Myeloma Study Group (nmsg). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x.

  7. Kumar S, Flinn I, Richardson PG. Randomized, multicenter, phase2 study (evolution) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012 May 10;119(19):4375-82.

  8. Sharma M, Khan H, Thall PF. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012;118(9):2507–15.

  9. Garderet L, Iacobelli S, Moreau P. Superiority of the triple combination of bortezomib–thalidomide–dexamethasone over the dual combination of thalidomide–dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: The mmvar/ifm2005-04 randomized phase iii trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(20):2475–82.

  10. 10.Sonneveld P, Schmidt–Wolf IG, Van der Holt B. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase iii hovon-65/gmmg-hd 4trial. J Clin Oncol. 2012;30:2946–55.

  11. 11.Cavo M, Pantani L, Petrucci MT. Bortezomib–thalidomide–dexamethasone is superior to thalidomide–dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120:9–11.

  12. 12.Neben K, Lokhorst HM, Jauch A. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion17p. Blood. 2012;119(4):940–8.

  13. 13.Kaura S, Dranitsaris G. Number needed to treat (nnt) as a measure of drug benefit: lenalidomide versus bortezomib for treatment of relapsed/refractory multiple myeloma (mm). J Clin Oncol [Internet]. 2012 [citado 4 Abr 2014];30: e18562. Disponible en: http://meetinglibrary.asco.org/content/96962-114

  14. 14.Rosinol L, Cibeira MT, Mateos MV. A phase3 pethema/gem randomised trial of posttransplant maintenance in multiple myeloma: superiority of bortezomib. Bone Marrow Transplant. 2013;47:S2.

  15. 15.Zinzani PL. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol. 2012;5:67. Published online 2012 Oct 22. doi: 10.1186/1756-8722-5-67.

  16. 16.Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013 Apr 24.

  17. 17.Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML, et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia. 2013 Nov;27(11):2242-4. doi:10.1038/leu.2013.101. Epub 2013 Apr 5.

  18. 18.Kamimura T, Miyamoto T, Yokota N, Takashima S, Chong Y, Ito Y, et al. Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen. Eur J Haematol. 2013 Feb;90(2):157-61. doi: 10.1111/ejh.12055. Epub 2013 Jan 9.

  19. 19.Takashima S, Miyamoto T, Kadawoki M, Ito Y, Aoki T,Takase T, et al. Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. Int J Hematol. 2014 Aug;100(2):159-64. doi: 10.1007/s12185-014-1611-1.

  20. 20.Kunami N, Katsuya H, Nogami R. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma. Anticancer Res. 2014 Oct;34(10):5287–94.

  21. 21.Holkova B, Kmieciak M, Perkins EB. Phase I trial of bortezomib (PS-341; NSC 681239) and ‘‘nonhybrid’’ (Bolus) infusion schedule of alvocidib (Flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15;20(22):5652–62.

  22. 22.Kumar SK, Berdeja JD, Niesvizky R. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). Blood. 2012;119:4375-82.

  23. 23.Niesvizky R, Martin TG, Bensinger WI. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15;19(8):2248-56. doi: 10.1158/1078-0432.

  24. 24.Hurchla MA, García-Gómez A, Hornick MC, Ocio EM, Li A, Blanco JF et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leucemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183.

  25. 25.Ribrag V, Tilly H, Casasnovas O. Efficacy and toxicity of two schedules of bortezomib in patients withrecurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Eur J Cancer. 2013 Mar;49(4):904-10. doi: 10.1016/j.ejca.2012.11.015. Epub 2012 Dec.

  26. 26.Furtado M, Johnson R, Kruger A. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015 Jan;168(1):55-62. doi: 10.1111/bjh.13101. Epub 2014 Aug 22.

  27. 27.Gerrie AS, Mikhael JR, Cheng L, Jiang H, Kukreti V, Panzarella T, et al. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol. 2013 Jun;161(6):802-10. doi: 10.1111/bjh.12325. Epub 2013 Apr 18.

  28. 28.Bose P, Batalo MS, Holkova B. Bortezomib for the treatment of non- Hodgkin’s lymphoma. Expert Opin Pharmacother. 2014 Nov;15(16):2443-59. doi: 10.1517/14656566.2014.965142. Epub 2014 Sep 29.

  29. 29.Goda AE, Erikson RL, Sakai T. Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies. Mol Oncol. 2015 Jan;9(1):309-22. doi: 10.1016/j.molonc.2014.08.010. Epub 2014 Sep 6.

  30. 30.Craig M, Hanna WT, Cabanillas F. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2014;166(6):920–8. doi: 10.1111/bjh.12991.

  31. 31.Yun H, Zhang HL, Wag HQ. Rituximab and Bortezomib(RB): a new effective regimen for refractory or relapsed indolent lymphoma. Med Oncol. 2015;32:353. doi: 10.1007/s12032-014-0353-5.




2020     |     www.medigraphic.com